The HEOR Workbench, From Synthesis to Value Dossier

Pull-quote: “A value dossier is an argument. It survives scrutiny exactly as well as the evidence chain underneath it, and not one footnote better.”

The last mile of evidence

Health economics and outcomes research sits between evidence synthesis and market access, and it answers a different examiner. Regulators ask whether the product works and is safe. Payers, health technology assessment bodies, and formulary committees ask what it is worth: comparative effectiveness against the standard of care, economic value, budget impact, burden of illness. The deliverable is the value dossier, a structured argument assembled from dozens of evidence claims, each of which someone on the other side of the table is paid to challenge.

The standard failure is architectural. Synthesis lives in one tool, economic inputs in another, the dossier in a third, and by the third handoff the claims have drifted from their sources. Every number retyped is a number unmoored.

One chain, many audiences

evidence base: SLRs, rapid reviews, living reviews,
internal documents and prior dossiers
      │
      ▼
synthesis layer: outcomes, comparators,
GRADE-rated evidence bodies
      │
      ▼
HEOR value modeling: burden of illness,
comparative value, economic inputs
      │
      ▼
value narrative: claims, each resolving
to its evidence
      │
      ├──► global value dossier, the master argument
      ├──► HTA and payer submissions, per market
      └──► formulary dossiers and objection handling

What a workbench changes

The workbench argument is continuity: run the chain on one governed platform and three chronic problems fall away.

Traceability

Every claim in the narrative resolves to synthesized evidence in the same workspace. Retrieval that combines graph and vector search can answer value questions with the citations attached, and internal decks, prior dossiers, and SOPs become a queryable evidence source beside the published literature. The claim and its source stay attached because they never crossed a tool boundary.

Currency

Value dossiers age the way reviews do. When a living review refresh changes a conclusion, the affected dossier claims are identifiable by lineage rather than by institutional memory, which turns dossier maintenance from archaeology into a work queue.

Auditability

The same append-only audit trail that governs screening and extraction governs the dossier’s evidence, so the answer to “where does this number come from” is a record, not a hunt. Deliverables leave the workbench submission-ready, with the chain intact behind them.

Reuse

Market access is serial. The same evidence base answers a global dossier, then each market’s assessment template, then the payer question that arrives eleven months later. When claims live as governed objects rather than paragraphs in a document, the second and the tenth deliverable are assemblies rather than rewrites, and objection handling starts from the claim’s evidence chain instead of a search through old PDFs. The dossier stops being a document project and becomes a view over the evidence.

The judgment that remains

The workbench does not make the argument. Value strategy, comparator selection, model structure, and market sequencing are human decisions, and HEOR and market access teams need their own path through the workbench precisely because their judgment is the product. What the workbench removes is the tax: retyped numbers, orphaned claims, and version drift between the evidence and the argument built on it.

Closing

Market access is where evidence work is finally cross-examined. A value dossier assembled in the same governed workspace as the synthesis beneath it answers that examination by construction: every claim traceable, every conclusion dated, every number still attached to where it came from. The argument is human. The chain of custody is the workbench’s job.